非霍奇金淋巴瘤幸存者既存心血管风险与后续心力衰竭
基于丹麦登记库纳入2000至2010年诊断的侵袭性非霍奇金淋巴瘤成人幸存者2508例及性别年龄匹配的普通人群对照7399例,随访至2012年。幸存者心衰风险较对照升高42%(HR 1.42,95%CI 1.07至1.88)。在多变量分析中,淋巴瘤诊断前既存内在心脏病与心衰风险升高相关(HR 2.71,95%CI 1.15至6.36),既存血管疾病与心衰无关联(P > .05)。
要点
- 非霍奇金淋巴瘤幸存者心衰风险较普通人群对照升高42%(HR 1.42,95%CI 1.07至1.88)。
- 诊断前既存内在心脏病与后续心衰风险升高相关(HR 2.71,95%CI 1.15至6.36)。
- 心血管危险因素数量与心衰风险相关:1个vs 0个HR 1.63(95%CI 1.07至2.47),≥2个vs 0个HR 2.86(95%CI 1.56至5.23),联合P < .01。
核心结论
- 在大型人群-based非霍奇金淋巴瘤幸存者队列中,既存心血管疾病与后续心衰风险升高相关;预防策略应考虑基线心血管健康状况。
研究设计与样本
- 利用丹麦登记库识别2000至2010年诊断的侵袭性非霍奇金淋巴瘤成人患者及性别年龄匹配的普通人群对照,随访心衰至2012年(自诊断后9个月起评估)。
- 共纳入2508例非霍奇金淋巴瘤幸存者和7399例普通人群对照;幸存者诊断时中位年龄62岁,56%为男性,随访中位2.5年。
- 采用Cox回归分析幸存者与普通人群对照间心衰风险差异;在幸存者中采用多变量Cox回归分析既存心血管因素(高血压、血脂异常、糖尿病)和既存心血管疾病与后续心衰的关联。
主要发现
- 幸存者较普通人群对照心衰风险升高42%(HR 1.42,95%CI 1.07至1.88)。
- 幸存者中有115例在随访期间诊断心衰;诊断前39%有≥1个心血管危险因素;92%接受含蒽环类方案治疗。
- 多变量分析中,淋巴瘤诊断前既存内在心脏病与心衰风险升高相关(HR 2.71,95%CI 1.15至6.36);既存血管疾病与心衰无关联(P > .05)。
- 与无心血管危险因素者相比,有1个心血管危险因素者心衰风险升高(HR 1.63,95%CI 1.07至2.47),有≥2个者心衰风险升高(HR 2.86,95%CI 1.56至5.23),联合P < .01。
临床怎么用
- 作者认为,预防策略应考虑基线心血管健康状况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose The use of anthracycline chemotherapy is associated with heart failure (HF) among survivors of non-Hodgkin lymphoma (NHL). We aimed to understand the contribution of preexisting cardiovascular risk factors to HF risk among NHL survivors. Methods Using Danish registries, we identified adults diagnosed with aggressive NHL from 2000 to 2010 and sex- and age-matched general-population controls. We assessed HF from 9 months after diagnosis through 2012. We used Cox regression analysis to assess differences in risk for HF between survivors and general population controls. Among survivors only, preexisting cardiovascular factors (hypertension, dyslipidemia, and diabetes) and preexisting cardiovascular disease were ascertained. We used multivariable Cox regression to model the association of preexisting cardiovascular conditions on subsequent HF. Results Among 2,508 survivors of NHL and 7,399 controls, there was a 42% increased risk of HF among survivors compared with general population controls (hazard ratio [HR], 1.42; 95% CI, 1.07 to 1.88). Among survivors (median age at diagnosis, 62 years; 56% male), 115 were diagnosed with HF during follow-up (median years of follow-up, 2.5). Before NHL diagnosis, 39% had ≥ 1 cardiovascular risk factor; 92% of survivors were treated with anthracycline-containing regimens. In multivariable analysis, intrinsic heart disease diagnosed before lymphoma was associated with increased risk of HF (HR, 2.71; 95% CI, 1.15 to 6.36), whereas preexisting vascular disease had no association with HF ( P > .05). Survivors with cardiovascular risk factors had an increased risk of HF compared with those with none (for 1 v 0 cardiovascular risk factors: HR, 1.63; 95% CI, 1.07 to 2.47; for ≥ 2 v 0 cardiovascular risk factors: HR, 2.86; 95% CI, 1.56 to 5.23; joint P < .01). Conclusion In a large, population-based cohort of NHL survivors, preexisting cardiovascular conditions were associated with increased risk of HF. Preventive approaches should take baseline cardiovascular health into account.
引用
- Salz T, Zabor EC, de Nully Brown P, et al. Preexisting Cardiovascular Risk and Subsequent Heart Failure Among Non-Hodgkin Lymphoma Survivors. J Clin Oncol. 2017. PMID: 28922087. doi:10.1200/JCO.2017.72.4211
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。